The importance of MDM2-mediated suppression of the TP53 pathway in neuroblastoma has convincingly been demonstrated in vivo using an MDM2-haploinsufficient mouse model in which tumor latency was delayed while tumor incidence and growth were remarkably reduced [6]. Here, TP53 is linked to neuroblastoma.